MAC Clinical Research, supporting Initiator Pharma as a full-service CRO, is pleased to announce the successful progression of participant enrolment with half already dosed in a Phase 2a clinical proof-of-concept study investigating Pudafensine.
Pudafensine is a candidate drug aimed at addressing vulvodynia, an often-overlooked chronic pain condition.
Initiator Pharma, a Danish clinical-stage biotech company, is advancing Pudafensine as part of its broader commitment to developing innovative therapies for conditions with significant unmet medical need. The company’s pipeline spans central and peripheral nervous system disorders, with Pudafensine representing a new therapeutic approach for chronic pain.
With no approved treatments currently available for vulvodynia, this study represents a meaningful step toward improving outcomes for those affected.
Dr John Connell, Chief Scientific Officer at MAC, said:
“We’re very pleased to have reached this point in the study. It’s been a great collaboration with Initiator Pharma so far, and it’s exciting to see the data come through – especially for patients who have very limited treatment options.”
Read the full statement from Initiator Pharma here.
